AbbVie to Showcase Breadth of Neuroscience Portfolio and Pipeline at American Academy of Neurology 2022 Annual Meeting Pharmaceutical Investing
European Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer Pharmaceutical Investing
Pfizer Announces Positive Top-line Results from Yearlong Phase 3 Trial of Etrasimod in Ulcerative Colitis, Underscoring Best-in-Class Potential Life Science Investing
ANZ Innovators Alimetry and The Clinician Among Five Winners In Medtronic APAC Innovation Challenge Medical Device Investing
Gilead Sciences Announces $24 Million in Grants to Help End the HIV Epidemic for Everyone, Everywhere Pharmaceutical Investing
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis Pharmaceutical Investing
AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH Pharmaceutical Investing
Knight Therapeutics Inc. places on The Globe and Mail's third-annual Women Lead Here benchmark of executive gender diversity Pharmaceutical Investing
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
